We hypothesized that SGLT2 inhibitor kidney outcome trials are more representative of people with co-existing T2D than those without T2D, and that the EMPA-KIDNEY study is more representative of the real-world CKD population than previous trials. The gene discussed is SLC5A2; the disease is chronic kidney disease.